Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

ELIQUIS

APIXABAN

Standard Dose
0.15MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview ELIQUIS is listed in Drugs@FDA under application 220073 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient APIXABAN Form and strength SUSPENSION;ORAL - 0.15MG Sponsor BRISTOL Submission history Latest submission status date: 2025-04-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview ELIQUIS is listed in Drugs@FDA under application 220073 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient APIXABAN Form and strength SUSPENSION;ORAL - 0.15MG Sponsor BRISTOL Submission history Latest submission status date: 2025-04-17 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.